The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.

James A Davis Abigail ShockleyHamza Hashmi

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)

BCMA targeting antibody drug conjugates, bispecific T-cell engagers, and CAR T-cell therapies have demonstrated clinical activity in myeloma patients and represent novel therapies in multiple myeloma treatment paradigm.

Keyphrases

multiple myeloma
newly diagnosed
end stage renal disease
cancer therapy
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
drug delivery
patient reported outcomes
replacement therapy
patient reported
smoking cessation